Social cognition is a crucial factor influencing development, progress, and treatment of psychiatric disorders. However, social cognition skills are insufficiently targeted by current treatment approaches. In particular, patients suffering from depression show an increased negative reaction to social exclusion and deficits in empathy. The 5HT-1A/2A receptor agonist psilocybin has previously...
Hallucinogens have been part of spiritual practice for millennia, but controversy surrounding their mind-manifesting effects led to their proscription by the mid-20th century, largely without evidence of harm or toxicity and despite nascent data suggesting therapeutic utility in treating depressive illnesses. This review explores their pharmacodynamic actions and the current limited data on...
Abstract The COMP006 Phase 3 trial showed that 39% of patients with treatment-resistant depression (TRD) respond to a single 25 mg dose of psilocybin, while 61% do not — at identical dose, protocol, and pharmacological exposure. No mechanistic explanation for this heterogeneity has been established. Here we propose and validate a two-threshold model in which the psilocybin dose-response...
A recent living systematic review in Nature Mental Health found psilocybin reduced depression symptoms across 12 randomized controlled trials, with pooled effect g = 0.90. The original analysis assessed publication bias using Egger’s test, non-significant — but this test has limited power with few studies and cannot produce a bias-corrected estimate. We re-analysed the same open dataset using...